Popular Longevity Supplement Fails to Meet Endpoint in Parkinson's Trial

(MedPage Today) -- Nicotinamide riboside, a form of vitamin B3 that increases cellular levels of nicotinamide adenine dinucleotide (NAD+), had no significant clinical benefit in early Parkinson's disease, the NOPARK randomized trial showed.
Commonly...